Q-omics provides the consensus-scored IGLV1-62 profile across patient tissues and cancer cell-line models. IGLV1-62 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLV1-62 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, IGLV1-62 RNA expression shows 6,907 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, COAD, and STAD as cancer lineages where IGLV1-62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLV1-62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLV1-62 survival associations across molecular data types. IGLV1-62 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLV1-62 RNA expression–survival associations across cancer types. High IGLV1-62 expression shows unfavorable associations in ACC and KIRP, but favorable associations in HNSC, BLCA, CESC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLV1-62 RNA expression.
This table summarizes IGLV1-62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLV1-62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLV1-62 shows lower tumor expression in COAD, STAD, BRCA, READ and LIHC and higher tumor expression in LUAD. The COAD box plot shows higher IGLV1-62 RNA expression in normal versus tumor tissue (log2 FC = −0.654, t-test p < 0.001).
This table shows molecular features associated with IGLV1-62 in patient tissues and cancer cell lines. In patient samples, IGLV1-62 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
